Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification
- PMID: 3567285
Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification
Abstract
When designing a clinical trial to test the equality of survival distributions for two treatment groups, the usual assumptions are exponential survival, uniform patient entry, full compliance, and censoring only administratively at the end of the trial. Various authors have presented methods for estimation of sample size or power under these assumptions, some of which allow for an R-year accrual period with T total years of study, T greater than R. The method of Lachin (1981, Controlled Clinical Trials 2, 93-113) is extended to allow for cases where patients enter the trial in a nonuniform manner over time, patients may exit from the trial due to loss to follow-up (other than administrative), other patients may continue follow-up although failing to comply with the treatment regimen, and a stratified analysis may be planned according to one or more prognostic covariates.
Similar articles
-
Sample size determination for comparing several survival curves with unequal allocations.Stat Med. 2004 Jun 15;23(11):1793-815. doi: 10.1002/sim.1771. Stat Med. 2004. PMID: 15160409
-
Sample size calculation for the weighted rank statistics with paired survival data.Stat Med. 2008 Jul 30;27(17):3350-65. doi: 10.1002/sim.3189. Stat Med. 2008. PMID: 18205148
-
A simple method for calculating power based on a prior trial.J Clin Epidemiol. 2010 Sep;63(9):992-7. doi: 10.1016/j.jclinepi.2009.10.011. Epub 2010 Jun 22. J Clin Epidemiol. 2010. PMID: 20573484
-
Variance estimation in clinical studies with interim sample size re-estimation.Biometrics. 2005 Jun;61(2):355-61. doi: 10.1111/j.1541-0420.2005.00315.x. Biometrics. 2005. PMID: 16011681
-
Calculation of sample size in survival trials: the impact of informative noncompliance.Biometrics. 2004 Sep;60(3):800-6. doi: 10.1111/j.0006-341X.2004.00231.x. Biometrics. 2004. PMID: 15339304
Cited by
-
Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.Contemp Clin Trials. 2020 Sep;96:106094. doi: 10.1016/j.cct.2020.106094. Epub 2020 Jul 31. Contemp Clin Trials. 2020. PMID: 32739495 Free PMC article. Clinical Trial.
-
The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS).J Thromb Thrombolysis. 2005 Jun;19(3):163-72. doi: 10.1007/s11239-005-1452-0. J Thromb Thrombolysis. 2005. PMID: 16082603 Clinical Trial.
-
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.Cancer Med. 2023 Jul;12(14):14988-14999. doi: 10.1002/cam4.6135. Epub 2023 May 24. Cancer Med. 2023. PMID: 37226421 Free PMC article. Clinical Trial.
-
Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks.Stat Med. 2018 Apr 15;37(8):1389-1401. doi: 10.1002/sim.7590. Epub 2017 Dec 27. Stat Med. 2018. PMID: 29282764 Free PMC article.
-
Expression of interleukin-8 receptor CXCR2 and suppressor of cytokine signaling-3 in astrocytic tumors.Mol Med. 2012 May 9;18(1):379-88. doi: 10.2119/molmed.2011.00449. Mol Med. 2012. PMID: 22231733 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical